Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐81

Overview of attention for article published in Biopharmaceutics & Drug Disposition, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#2 of 422)
High Attention Score compared to outputs of the same age (96th percentile)

Mentioned by

news: 11 news outlets

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 2 Mendeley

Summary News Wikipedia Dimensions citations

So far, Dimensions has found 4 publications that cite this research output.

4

The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.

New Imidazodiazepine Analogue, 5‑(8-Bromo-6-(pyridin-2-yl)‑4H‑benzo[f]imidazo[1,5‑a][1,4]diazepin-3-yl)oxazole, Provides a Simplified Synthetic Scheme, High Oral Plasma and Brain Exposures, and Produces Antiseizure Efficacy in Mice, and Antiepileptogenic Activity in Neural Networks in Brain Slices from a Patient with Mesial Temporal Lobe Epilepsy

Article in ACS Chemical Neuroscience (January 2024)

Comparative anticonvulsant activity of the GABAkine KRM‐II‐81 and a deuterated analog

Article in Drug Development Research (February 2023)

Structural analogs of the GABAkine (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-α][1,4]diazepin-3-yl) oxazole) (KRM-II-81) are orally bioavailable anticonvulsants without sedation1

Article in Journal of Pharmacology and Experimental Therapeutics (February 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.